Organization · Venture Capital
Telegraph Hill Partners
Telegraph Hill Partners is a San Francisco-based venture capital firm that specializes in growth capital investments in life sciences, medical devices, and healthcare companies. Founded in 2001, it partners with innovative firms to support their expansion and innovation.
Overview
What Telegraph Hill Partners does
What Telegraph Hill Partners is
Telegraph Hill Partners is a San Francisco-based venture capital firm that specializes in growth capital investments in life sciences, medical devices, and healthcare companies. Founded in 2001, it partners with innovative firms to support their expansion and innovation.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2001
- Approximate age
- About 25 years
- Structured capabilities
- Funder
- Last reviewed
- April 23, 2026
Official channels
Find Telegraph Hill Partners elsewhere
Open the official website or a supported primary organization account.
Capability profile
Telegraph Hill Partners as a funder
Investment thesis
Telegraph Hill Partners provides growth capital to life science and healthcare companies with validated technologies and established customer bases, supporting them throughout their lifecycle.
Focus narrative
The firm invests in private life science and healthcare companies that possess novel technologies, a solid customer base, and innovative management teams. Key areas of focus include discovery tools and automation, diagnostics, healthcare IT, and medical devices. They often serve as the first institutional investor for boot-strapped companies, providing capital and strategic guidance for growth equity, acquisitions, and management buyouts.
Value beyond capital
Telegraph Hill Partners adds value to its portfolio companies by providing not only capital but also strategic guidance and support for growth initiatives, acquisitions, and management buyouts. Their extensive experience in the life sciences and healthcare sectors enables them to assist companies in navigating challenges and seizing opportunities for expansion.
Focus and fit
- Stages
- Seed · Series A · Series B · Growth Equity
- Sectors
- Healthcare · Biotech · Medical Devices · Diagnostics
- Regions
- North AmericaUnited States
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 6
- Recorded notable exits
- Akoya Biosciences, Asuragen, and LDR
Portfolio context
Notable portfolio companies include: AccuMetrics: Developer of point-of-care diagnostics in cardiovascular and neurovascular disease areas, acquired by ITC Nexus in 2013. Agena Bioscience: Offers the MassARRAY® System for nucleic acid detection, acquired by Mesa Laboratories in 2021. Akoya Biosciences: Specializes in high-parameter proteomic profiling of tissues, went public in 2021 and acquired by Quanterix in 2025. Asuragen: Focuses on personalized medicine for cancer patients, acquired by Bio-Techne in 2021. LDR: Develops innovative spinal implants, went public in 2013 and acquired by Zimmer Biomet in 2016. Nimble Therapeutics: Utilizes chemical synthesis for drug discovery, acquired by AbbVie in 2025.
Common questions
What to know about Telegraph Hill Partners
Upseed classifies Telegraph Hill Partners under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 23, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.